Compare Ascendis Pharma A/S (ASND) vs Deutsche Bank AG (DB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Deutsche Bank AG — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Deutsche Bank AG trades at $35.72 (market cap $68.30B). The key difference: Deutsche Bank AG is far larger — about 3.9× Ascendis Pharma A/S's market cap, and Deutsche Bank AG pays a 3.25% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DB | |
|---|---|---|
Market Cap | $17.74B | $68.30B |
Sector | Health | Financials |
52-Week High | $277.18 | $40.33 |
52-Week Low | $163.32 | $28.37 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Deutsche Bank (DB) trades at $35.77, up 1.05% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamental momentum with Q1 2026 EPS beating expectations at $1.24 versus $1.15, and net income margin improving to 21.98% in 2025. Recent news includes expansion into Saudi Arabia and a dividend of $1.00 payable in June 2026, reflecting strategic growth initiatives.
Outlook is cautiously optimistic given low P/E of 9.94 and P/B of 0.77, suggesting undervaluation, but risks include volatile cash flows with a net outflow of $33.10B in 2024 and mixed analyst sentiment with only 21% buy ratings. Investors should weigh earnings consistency against macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
